Nov 20, 2025 · Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to developing novel medicines.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We …

Check out the drug pipeline for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing synthetic lethal therapies.

Learn about scientifc discovery platorm at Repare Therapeutics, a clinical-stage precision oncology company developing novel, synthetic lethal medicines.

Learn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.

Mar 31, 2025 · Press releases for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.

Repare is developing a small molecule inhibitor of polymerase theta, or Polθ, a SL target associated with BRCA mutations and other genomic alterations.

Repare Therapeutics is recruiting patients in the U.S. and other countries for the following active clinical trials. Please follow the links below for more information for each study and site location.

Mar 3, 2025 · Repare initiated the Phase 1 clinical trial of RP-3467 (POLAR) in the fourth quarter of 2024, dosing patients alone and in combination with the poly-ADP ribose polymerase …

Jun 1, 2022 · Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx® screening, in …